Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients

British Journal of Haematology

Volumn 147, Issue 5, 2009, Pages 744-751

  Zanninelli, Giuliana ^a   Breuer, William ^b   Cabantchik, Zvi I ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b S EUGENIO HOSPITAL   (Italy)

Author keywords

Chelation; Iron; Thalassaemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON;

ADULT; ARTICLE; CHELATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IRON BLOOD LEVEL; LABILE PLASMA IRON; MALE; PATIENT MONITORING; PRIORITY JOURNAL; THALASSEMIA MAJOR; TREATMENT DURATION;

ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; CIRCADIAN RHYTHM; DEFEROXAMINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PYRIDONES;

EID: 70449363999     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07907.x     Document Type: Article

References (32)

1. Alymara, V., Bourantas, D., Chaidos, A., Bouranta, P., Gouva, M., Vassou, A., Tzouvara, E. Bourantas, K.L. (2004) Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. The Hematology Journal, 5, 475 479.
2. Breuer, W., Hershko, C. Cabantchik, Z.I. (2000) The importance of non-transferrin bound iron in disorders of iron metabolism. Transfusion Science, 23, 185 192.
3. Cabantchik, Z.I., Breuer, W., Zanninelli, G. Cianciulli, P. (2005) LPI-labile plasma iron in iron overload. Best Practice & Research. Clinical Haematology, 18, 277 287.
4. Cabantchik, Z.I., Fibach, E. Breuer, W. (2009). Can labile plasma iron (LPI) and labile cell iron (LCI) levels serve as early indicators of chelation efficacy in iron overload? BloodMed.com. http://www.bloodmed.com/800000/mini- reviews1.asp?id=254.
5. Cappellini, M.D. Pattoneri, P. (2009) Oral iron chelators. Annual Review of Medicine, 60, 25 38.
6. Daar, S., Pathare, A., Nick, H., Kriemler-Krahn, U., Hmissi, A., Habr, D. Taher, A. (2009) Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. European Journal of Haematology, 82, 454 459.
7. El-Beshlawy, A., Manz, C., Naja, M., Eltagui, M., Tarabishi, C., Youssry, I., Sobh, H., Hamdy, M., Sharaf, I., Mostafa, A., Shaker, O., Hoffbrand, A.V. Taher, A. (2008) Iron chelation in thalassemia: combined or monotherapy? The Egyptian Experience. Annals of Hematology, 87, 545 550.
8. Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. Cabantchik, Z.I. (2003) Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood, 102, 2670 2677.
9. Flowers, C.A., Kuizon, M., Beard, J.L., Skikne, B.S., Covell, A.M. Cook, J.D. (1986) A serum ferritin assay for prevalence studies of iron deficiency. American Journal of Hematology, 23, 141 151.
10. Galanello, R. (2005) Combined therapy with deferiprone and desferrioxamine in Thalassemia major. Haematologica, 90, 1163 1168.
11. Glickstein, H., Ben El, R., Shvartsman, M. Cabantchik, Z.I. (2005) Intracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cells. Blood, 106, 3242 3250.
12. Glickstein, H., Ben El, R., Link, G., Breuer, W., Konijn, A.M., Hershko, C., Nick, H. Cabantchik, Z.I. (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood, 108, 3195 3203.
13. Hershko, C., Graham, G., Bates, G.W. Rachmilewitz, E.A. (1978) Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. British Journal of Haematology, 40, 255 263.
14. Hider, R.C. (2002) Nature of nontransferrin-bound iron. European Journal of Clinical Investigation, 32 (Suppl. 1 50 54.
15. ICSH (1978) Recommendations for measurement of serum iron in human blood. British Journal of Haematology, 38, 291 294.
16. Jensen, P.D. (2004) Evaluation of iron overload. British Journal of Haematology, 124, 697 711.
17. Kattamis, A., Ladis, V., Berdousi, H., Kelekis, N.L., Alexopoulou, E., Papasotiriou, I., Drakaki, K., Kaloumenou, I., Galani, A. Kattamis, C. (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Molecules and Diseases, 36, 21 25.
18. ®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood, 110, abstract 1470.
19. Mourad, F.H., Hoffbrand, A.V., Sheikh-Taha, M., Koussa, S., Khoriaty, A.I. Taher, A. (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. British Journal of Haematology, 121, 187 189.
20. Piga, A., Longo, F., Duca, L., Roggero, S., Vinciguerra, T., Calabrese, R., Hershko, C. Cappellini, M.D. (2009) High non-transferrin bound iron levels and heart disease in Thalassemia major. American Journal of Hematology, 84, 29 33.
21. Pootrakul, P., Sirankapracha, P., Sankote, J., Kachintorn, U., Maungsub, W., Sriphen, K., Thakernpol, K., Atisuk, K., Fucharoen, S., Chantraluksri, U., Shalev, O. Hoffbrand, A.V. (2003) Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. British Journal of Haematology, 122, 305 310.
22. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. Cabantchik, Z.I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood, 104, 1504 1510.
23. Porter, J.B. (2005) Pathophysiology of iron overload. Hematology/Oncology Clinics of North America, 19 (Suppl. 1 7 12.
24. Porter, J.B. Davis, B.A. (2002) Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice & Research. Clinical Haematology, 15, 329 368.
25. Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T. Evans, P. (2005) Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Annals of the New York Academy of Sciences, 1054, 155 168.
26. ®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year Epic trial. Blood, 110, abstract 963.
27. St Pierre, T.G., Clark, P.R. Chua-Anusorn, W. (2005) Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Annals of the New York Academy of Sciences, 1054, 379 385. (Pubitemid 43031045)
28. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. Pennell, D.J. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in Thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876 1884.
29. Torrance, J.D. Bothwell, T.H. (1968) A simple technique for measuring storage iron concentrations in formalinized liver samples. The South African Journal of Medical Sciences, 33, 9 11.
30. Wonke, B., Wright, C. Hoffbrand, A.V. (1998) Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology, 103, 361 364.
31. Wood, J.C. (2008) Cardiac iron across different transfusion-dependent diseases. Blood Reviews, 22 (Suppl. 2 S14 S21.
32. Zanninelli, G., Sorrentino, F., Iazzoni, R., Marzano, R., Breuer, W., Cabantchik, Z.I. Cianciulli, P. (2007) Deferasirox (Exjade, IC:L670) efficiently removes labile plasma iron as compared to desferrioxamine and deferiprone: a 24 h monitoring study in thalassaemia patients. American Journal of Hematology, 82, 524, abstract O29.